Perrigo announced that its partner, Cobrek Pharmaceuticals, received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Betamethasone Valerate Foam 0.12%, the generic version Stiefel LaboratoriesLuxiq Foam.

Luxiq is a topical steroid indicated for the relief of corticosteroid-responsive skin conditions of the scalp (scalp psoriasis). It contains anti-inflammatory, antipruritic, and vasoconstrictive properties. It is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins.

Betamethasone Valerate Foam 0.12% is expected to commence shipping on January 15, 2013.

For more information call (800) 719-9260 or visit